Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672035 · ClinicalTrials.gov registry record · Phase 2
Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study
A Phase 2 study, sponsored by Intercell USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT00672035 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 406 participants.
The verdict
NCT00672035, a Phase 2 study, has completed, sponsored by Intercell USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses. The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the skin preparation system. Another secondary purpose is to compare the safety and the body's immune response to LT patches placed on the upper arm versus the lower back.
Interventions
- BIOLOGICAL Biological: heat-labile enterotoxin of E. coli (LT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672035
The ClinicalTrials.gov registry entry for NCT00672035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercell USA, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biological: heat-labile enterotoxin of E. coli (LT) is the first listed.
NCT00672035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00672035 about?
NCT00672035 is a clinical study titled "Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study". The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses. The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the skin preparation system. Another secondary purpose is to compare the ...
What is the current status of trial NCT00672035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00672035?
The interventions under investigation include: Biological: heat-labile enterotoxin of E. coli (LT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00672035?
This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.